SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug Markle who wrote (5453)10/5/1998 2:35:00 PM
From: John Metcalf  Read Replies (1) of 6136
 
Doug, my understanding is that the rights transfer with the shares, and will continue to do so, except to a buyer of 15% or more of the company shares. If a fellow SI-er doesn't come along soon and give a more definitive opinion, surely Ms. Nichols would clarify this issue.

Since the value of the rights is determined by Board action subsequent to the "trigger" event, that value would be set to zero to facilitate a friendly merger, if one is ever proferred and accepted.

I have no knowledge that there is such an offer, nor ever will be.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News